Risk of Adverse Events After Anti-TNF Treatment for Inflammatory Rheumatological Disease. A Meta-Analysis

• Κύριοι συγγραφείς: Ju Li (Συγγραφέας), Zhongyuan Zhang (Συγγραφέας), Xinhua Wu (Συγγραφέας), Jie Zhou (Συγγραφέας), Deqian Meng (Συγγραφέας), Ping Zhu (Συγγραφέας)
• Μορφή: Βιβλίο
• Έκδοση: Frontiers Media S.A., 2021-11-01T00:00:00Z.
• Θέματα: article
• Διαθέσιμο Online: Connect to this object online.

Background: Adalimumab, golimumab, infliximab, certolizumab, and etanercept are five anti-tumor necrosis factor (anti-TNF) medicines that have been approved for use in rheumatology. Apart from their well-established therapeutic usefulness, -it is unclear to what extent -they are linked to an increas...